Listen Live
Donate
 on air
    Schedule

    KCRW

    Read & Explore

    • News
    • Entertainment
    • Food
    • Culture
    • Events

    Listen

    • Live Radio
    • Music
    • Podcasts
    • Full Schedule

    Information

    • About
    • Careers
    • Help / FAQ
    • Newsletters
    • Contact

    Support

    • Become a Member
    • Become a VIP
    • Ways to Give
    • Shop
    • Member Perks

    Become a Member

    Donate to KCRW to support this cultural hub for music discovery, in-depth journalism, community storytelling, and free events. You'll become a KCRW Member and get a year of exclusive benefits.

    DonateGive Monthly

    Copyright 2026 KCRW. All rights reserved.

    Report a Bug|Privacy Policy|Terms of Service|
    Cookie Policy
    |FCC Public Files|

    Back to Press Play with Madeleine Brand

    Press Play with Madeleine Brand

    This long-haul COVID patient sees no major improvement in symptoms after second vax dose

    “After the first one, I thought that I did see some improvement with some symptoms, like shortness of breath, maybe some of the GI symptoms and some of the joint pain. But that was kind of short-lived. And then after the second one, I didn't really see any difference,” Cliff Morrison says.

    • rss
    • apple-podcasts
    • spotify
    • Share
    By Madeleine Brand • Aug 31, 2021 • 10m Listen

    For many long-haul COVID patients, symptoms have persisted for months, or even more than a year, after their initial infection. KCRW checks in with two guests we’ve spoken to before: Dr. Michael Peluso, a clinical fellow at the UC San Francisco School of Medicine, is helping run a two-year study of long-haul COVID patients; and Cliff Morrison, a patient in that study and a health care administrator in the Bay Area.

    Morrison received his first dose of the Moderna vaccine earlier this year. But after experiencing a 102-degree fever, gastrointestinal issues, nausea, and trouble breathing, his doctors advised him to hold off on the second dose. He finally got his second dose a few weeks ago as the Delta variant surged. But he says it had little effect on his symptoms.

    “After the first one, I thought that I did see some improvement with some symptoms, like shortness of breath, maybe some of the GI symptoms and some of the joint pain,” Morrison says. “But that was kind of short-lived. And then after the second one, I didn't really see any difference.”

    Dr. Peluso says it’s too soon to know if vaccinated people who get breakthrough infections may suffer from long-term COVID. And there’s still no universally recommended treatment for long-term COVID symptoms.

    “I think what we've learned over the last year is that this is a real condition that really affects people's lives, and that has come to be well-accepted,” Dr. Peluso says. “I think that's a major accomplishment of both the research and advocacy community over the last year. And now we and others are trying to actually get some answers about the biological processes that cause these symptoms, and kind of the interface between the biology and the whole person.”

    • https://images.ctfassets.net/2658fe8gbo8o/AvYox6VuEgcxpd20Xo9d3/769bca4fbf97bf022190f4813812c1e2/new-default.jpg?h=250

      Madeleine Brand

      Host, 'Press Play'

    • KCRW placeholder

      Sarah Sweeney

      Vice President of Talk Programming, KCRW

    • KCRW placeholder

      Angie Perrin

      Producer, Press Play

    • KCRW placeholder

      Michell Eloy

      Line Editor, Press Play

    • KCRW placeholder

      Dr. Michael Peluso

      clinical fellow at UCSF’s School of Medicine involved in a two-year study of long COVID patients

    • KCRW placeholder

      Cliff Morrison

      health care administrator and long-haul COVID-19 patient

      NewsCoronavirusHealth & Wellness
    Back to Press Play with Madeleine Brand